TWST Stock Forecast & Price Target

Twist Bioscience is a leading player in the growing synthetic biology market with its unique and patent-protected DNA synthesis platform. The company's strong focus on cost efficiency and expanding capacity bodes well for its financial performance in the near and long term. Furthermore, the growing demand for synthetic DNA in various industries, including healthcare and technology, and the potential for new product launches and strategic acquisitions provide additional upside potential. While there are some risks to consider, such as slower-than-expected growth or increased competition, these are outweighed by the company's strong fundamentals and multiple potential catalysts for growth. Therefore, a buy rating is appropriate for this stock.

Twist Bioscience is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. While the company operates in a competitive market and faces pricing pressure from integrated incumbents, its unique silicon-based DNA synthesis platform offers a cost-effective solution for researchers. However, there is significant execution risk around margins and operating leverage, and the recent stock surge driven by Anthropic's protein design research was a benchmark evaluation, not a strategic or commercial partnership. Additionally, the company's profitability story depends on continued gross margin improvement and disciplined expense control, and while it raised guidance for FY26, it was accompanied by increased investments and cost initiatives. Furthermore, while there is potential from accelerating demand in AI-enabled drug discovery, there is no guarantee that the company will be able to capitalize on this opportunity.